Daniel Shu

1.0k total citations · 1 hit paper
15 papers, 319 citations indexed

About

Daniel Shu is a scholar working on Oncology, Epidemiology and Immunology. According to data from OpenAlex, Daniel Shu has authored 15 papers receiving a total of 319 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 5 papers in Epidemiology and 4 papers in Immunology. Recurrent topics in Daniel Shu's work include Cancer Immunotherapy and Biomarkers (5 papers), Hepatocellular Carcinoma Treatment and Prognosis (3 papers) and Influenza Virus Research Studies (2 papers). Daniel Shu is often cited by papers focused on Cancer Immunotherapy and Biomarkers (5 papers), Hepatocellular Carcinoma Treatment and Prognosis (3 papers) and Influenza Virus Research Studies (2 papers). Daniel Shu collaborates with scholars based in United States, United Kingdom and New Zealand. Daniel Shu's co-authors include Mark Yarchoan, Elizabeth M. Jaffee, Luciane T. Kagohara, Matteo Cesaroni, Philip L. Cohen, Brendan Hilliard, Jenny P.‐Y. Ting, Yuxuan Zhen, Olivier Godeaux and Renzo Perales‐Linares and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Hepatology.

In The Last Decade

Daniel Shu

15 papers receiving 315 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial

2024 111 citations Mark Yarchoan, Edward Gane et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel Shu United States	6	143	107	98	84	50	15	319
Serena Chang United States	8	235 1.6×	100 0.9×	157 1.6×	73 0.9×	154 3.1×	17	423
Zeming Chen China	5	224 1.6×	125 1.2×	62 0.6×	128 1.5×	82 1.6×	10	408
Sabrina Mazouz Canada	6	178 1.2×	76 0.7×	62 0.6×	90 1.1×	50 1.0×	9	305
Alessandra Ferrera Italy	9	172 1.2×	48 0.4×	127 1.3×	65 0.8×	16 0.3×	12	466
Michelle Chung United States	6	145 1.0×	45 0.4×	193 2.0×	129 1.5×	167 3.3×	9	458
Leyre Silva Spain	12	218 1.5×	135 1.3×	72 0.7×	134 1.6×	121 2.4×	17	438
Ganit Yarden Israel	6	278 1.9×	189 1.8×	47 0.5×	114 1.4×	23 0.5×	7	440
Julia Benckert Germany	7	157 1.1×	48 0.4×	47 0.5×	117 1.4×	62 1.2×	12	370
Ahmad Zaheen Canada	10	140 1.0×	43 0.4×	69 0.7×	123 1.5×	27 0.5×	15	303

Countries citing papers authored by Daniel Shu

Since Specialization

Citations

This map shows the geographic impact of Daniel Shu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Shu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Shu more than expected).

Fields of papers citing papers by Daniel Shu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Shu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Shu. The network helps show where Daniel Shu may publish in the future.

Co-authorship network of co-authors of Daniel Shu

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Shu. A scholar is included among the top collaborators of Daniel Shu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Shu. Daniel Shu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Baretti, Marina, Vaibhav Sahai, Daniel Shu, et al.. (2025). Deep immune profiling of intrahepatic cholangiocarcinoma with CODEX multiplexed imaging. Hepatology Communications. 9(3). 4 indexed citations

Yarchoan, Mark, Edward Gane, Thomas U. Marron, et al.. (2024). Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial. Nature Medicine. 30(4). 1044–1053. 111 indexed citations breakdown →

D’Alessio, Antonio, Bernardo Stefanini, Claudia Angela Maria Fulgenzi, et al.. (2024). Qualification of major pathological response as a surrogate endpoint for relapse-free survival following neoadjuvant immunotherapy for hepatocellular carcinoma.. Journal of Clinical Oncology. 42(3_suppl). 506–506. 2 indexed citations

Shu, Daniel & Dimitrios N. Sidiropoulos. (2024). Maturation of Tertiary Lymphoid Structures. Methods in molecular biology. 2864. 43–55. 3 indexed citations

Alden, Stephanie, Chester Kao, Daniel Shu, et al.. (2023). Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma. Cancer Research Communications. 3(7). 1312–1317. 21 indexed citations

Alden, Stephanie, Chester Kao, Daniel Shu, et al.. (2023). Salvage ipilimumab plus nivolumab in advanced hepatocellular carcinoma after prior anti-PD-(L)1 blockade.. Journal of Clinical Oncology. 41(16_suppl). 4091–4091. 2 indexed citations

Zabransky, Daniel J., Ludmila Danilova, James M. Leatherman, et al.. (2022). Profiling of syngeneic mouse HCC tumor models as a framework to understand anti–PD‐1 sensitive tumor microenvironments. Hepatology. 77(5). 1566–1579. 38 indexed citations

Shu, Daniel, Ludmila Danilova, Qingfeng Zhu, et al.. (2022). Abstract 1323: 12-chemokine gene signature identifies major pathologic response in patients with hepatocellular carcinoma treated with neoadjuvant nivolumab and cabozantinib. Cancer Research. 82(12_Supplement). 1323–1323. 2 indexed citations

Wu, Lawrence W., S. M. Qasim Hussaini, Jae W. Lee, et al.. (2022). Transformation of metastatic nonfunctioning pancreatic neuroendocrine tumor into insulinoma—two case reports. 5. 6–6. 2 indexed citations

10.

Godeaux, Olivier, Martina Kovac, Daniel Shu, et al.. (2017). Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults ≥ 50 years of age with a prior history of herpes zoster: A phase III, non-randomized, open-label clinical trial. Human Vaccines & Immunotherapeutics. 13(5). 1051–1058. 45 indexed citations

11.

Shu, Daniel, Yuxuan Zhen, Brendan Hilliard, et al.. (2016). Prion‐like Aggregation of Mitochondrial Antiviral Signaling Protein in Lupus Patients Is Associated With Increased Levels of Type I Interferon. Arthritis & Rheumatology. 68(11). 2697–2707. 56 indexed citations

12.

Shao, Wen-Hai, et al.. (2014). Aggregation of MAVS antiviral protein suggests a mechanism for increased type I interferon production in SLE. Arthritis Research & Therapy. 16(Suppl 1). A19–A19. 1 indexed citations

13.

Reisinger, Keith S., et al.. (2012). Safety and tolerability of a 6‐week course of oseltamivir prophylaxis for seasonal influenza in children. Influenza and Other Respiratory Viruses. 7(1). 11–13. 3 indexed citations

14.

Langley, Joanne M., F. Y. Aoki, Brian J. Ward, et al.. (2011). A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness. Vaccine. 29(10). 1921–1928. 28 indexed citations

15.

Dai, Wei, et al.. (2001). [IFN-r/IL-4 expression in peripheral blood mononuclear cells of the patients with chronic severe hepatitis].. PubMed. 9 Suppl. 64–5. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact